Search Results - "Catenacci, D."

Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer by Schrock, A.B., Ouyang, C., Sandhu, J., Sokol, E., Jin, D., Ross, J.S., Miller, V.A., Lim, D., Amanam, I., Chao, J., Catenacci, D., Cho, M., Braiteh, F., Klempner, S.J., Ali, S.M., Fakih, M.

“…Microsatellite instability (MSI) is a biomarker for response to immune checkpoint inhibitors (ICPIs). PD-1 inhibitors in metastatic colorectal carcinoma (mCRC)…”
Get full text

The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer by Berchuck, J.E., Facchinetti, F., DiToro, D.F., Baiev, I., Majeed, U., Reyes, S., Chen, C., Zhang, K., Sharman, R., Uson Junior, P.L.S., Maurer, J., Shroff, R.T., Pritchard, C.C., Wu, M.-J., Catenacci, D.V.T., Javle, M., Friboulet, L., Hollebecque, A., Bardeesy, N., Zhu, A.X., Lennerz, J.K., Tan, B., Borad, M., Parikh, A.R., Kiedrowski, L.A., Kelley, R.K., Mody, K., Juric, D., Goyal, L.

“…Targeted therapies have transformed clinical management of advanced biliary tract cancer (BTC). Cell-free DNA (cfDNA) analysis is an attractive approach for…”
Get full text

Tackling diversity within diversity by Lomnicki, S., Setia, N., Catenacci, D.V.T.

Get full text

Quantitative proteomic analysis of HER2 expression in the selection of gastric cancer patients for trastuzumab treatment by An, E., Ock, C.-Y., Kim, T.-Y., Lee, K.-H., Han, S.-W., Im, S.-A., Kim, T.-Y., Liao, W.-L., Cecchi, F., Blackler, A., Thyparambil, S., Kim, W.H., Burrows, J., Hembrough, T., Catenacci, D.V.T., Oh, D.-Y., Bang, Y.-J.

“…A wide range of response rates have been reported in HER2-positive gastric cancer (GC) patients treated with trastuzumab. Other HER2-targeted therapies for GC…”
Get full text

195TiP GLOW: Phase III study of first-line zolbetuximab + CAPOX versus placebo + CAPOX in Claudin18.2⁺/HER2⁻ advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ) by Xu, R-H., Ajani, J.A., Al-Batran, S-E., Bang, Y-J., Catenacci, D., Enzinger, P.C., Ilson, D.H., Kim, S., Lordick, F., Shitara, K., van Cutsem, E., Arozullah, A., Park, J.W., Shah, M.A.

Get full text

Interim results of fight-202, a phase II, open-label, multicenter study of INCB054828 in patients (pts) with previously treated advanced/metastatic or surgically unresectable cholangiocarcinoma (CCA) with/without fibroblast growth factor (FGF)/FGF receptor (FGFR) genetic alterations by Hollebecque, A., Borad, M., Sahai, V., Catenacci, D.V.T., Murphy, A., Vaccaro, G., Paulson, A., Oh, D.-Y., Féliz, L., Lihou, C., Zhen, H., Abou-Alfa, G.K.

Get full text

Trifluridine/tipiracil versus placebo for third or later lines of treatment in metastatic gastric cancer: an exploratory subgroup analysis from the TAGS study by Tabernero, J., Shitara, K., Zaanan, A., Doi, T., Lorenzen, S., Van Cutsem, E., Fornaro, L., Catenacci, D.V.T., Fougeray, R., Moreno, S.R., Azcue, P., Arkenau, H.-T., Alsina, M., Ilson, D.H.

“…Metastatic gastric cancer and cancer of the esophagogastric junction (GC/EGJ) is an aggressive disease with poor prognosis. In the TAGS study,…”
Get full text

Margetuximab with retifanlimab as first-line therapy in HER2+/PD-L1+ unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort A by Catenacci, D.V.T., Kang, Y.-K., Yoon, H.H., Shim, B.Y., Kim, S.T., Oh, D.-Y., Spira, A.I., Ulahannan, S.V., Avery, E.J., Boland, P.M., Chao, J., Chung, H.C., Gardner, F., Klempner, S.J., Lee, K.-W., Oh, S.C., Peguero, J., Sonbol, M.B., Shen, L., Moehler, M., Sun, J., Li, D., Rosales, M.K., Park, H.

“…Human epidermal growth factor receptor 2 (HER2)-positive metastatic gastric and gastroesophageal adenocarcinoma (GEA) is globally treated with chemotherapy…”
Get full text

Biomarker-guided enrichment of the antitumor activity of margetuximab (M) plus pembrolizumab (P) in patients with advanced HER2+ gastric adenocarcinoma (GEA) by Catenacci, D.V.T., Park, H., Uronis, H.E., Kang, Y.-K., Ng, M., Gold, P., Lacy, J., Enzinger, P.C., Park, S., Lee, K.-W., Yen, J., Odegaard, J., Franovic, A., Baughman, J., Muth, J., Wynter-Horton, A., Wu, T., Wigginton, J., Davidson-Moncada, J.K., Bang, Y.-J.

Get full text

A novel framework for evaluating biomarker response relationships in immuno-oncology (IO) by Evelhoch, J.L., Mogg, R., Cristescu, R., Aurora-Garg, D., Chow, L.Q., Loi, S., Catenacci, D.V.T., Matulonis, U.A., Ott, P.A., Antonarakis, E.S., Poehlein, C.H., Joe, A., Keefe, S.M., Kang, P., Karantza, V., Cheng, J., Rubin, E.H.

Get full text

An open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202 by Vogel, A., Sahai, V., Hollebecque, A., Vaccaro, G.M., Melisi, D., Al Rajabi, R.M., Paulson, A.S., Borad, M.J., Gallinson, D., Murphy, A.G., Oh, D.-Y., Dotan, E., Catenacci, D.V., Van Cutsem, E., Lihou, C.F., Zhen, H., Veronese, M.L., Abou-Alfa, G.K.

“…Fibroblast growth factor receptor 2 (FGFR2) fusions and rearrangements are clinically actionable genomic alterations in cholangiocarcinoma (CCA). Pemigatinib…”
Get full text

Safety and efficacy of HER2 blockade by trastuzumab-based chemotherapy-containing combination strategies in HER2+ gastroesophageal adenocarcinoma by Catenacci, D.V.T., Chung, H.C., Shen, L., Moehler, M., Yoon, H.H., Rosales, M.K., Kang, Y.-K.

“…Since completion of the Trastuzumab for Gastric Cancer study, trastuzumab with doublet chemotherapy (a fluoropyrimidine and a platinum) has been the…”
Get full text

2397 Evaluation of MET using FISH, IHC, or mass spectrometry as a prognostic biomarker in patients with gastroesophageal cancer by Catenacci, D, Shen, J, Liao, W.L, Oliner, K, Ang, A, Loberg, R, O'Day, E, Xu, P, Henderson, L, Cecchi, F, Burrows, J, Hembrough, T, Ruzzo, A, Graziano, F

Get full text

Development of Quantitative Gastrointestinal Carcinoma (GEC and CRC) SRM Assays for Use in FFPE Tumor Tissues by Hembrough, T.A., Catenacci, D. V. T, Liao, W.L., Thyparambil, S., Xu, P., Henderson, L., Burrows, J.

Get full text

561 Development of a Quantitative Gastroesophageal Cancer Selected Reaction Monitoring Mass Spectrometric Multiplex Assay for Use in FFPE Tumor Tissues by Catenacci, D, Xu, P, Henderson, L, Liao, W, Burrows, J, Hembrough, T

Get full text

820 Development of a Quantitative RON SRM Assay for Use in Formalin Fixed Tumor Tissues by Catenacci, D, Henderson, L, Xu, P, Liao, W, Burrows, J, Hembrough, T

Get full text

537 Absolute quantitation of MET using mass spectrometry for clinical application: assay precision, stability, and correlation with MET gene amplification in FFPE tumor tissue by Cecchi, F, Liao, W.L, Thyparambil, S, Bengali, K, Uzzell, J, Darflar, M, Krizman, D, Burrows, J, Hembrough, T, Veenstra, T, Bottaro, D.P, Karrison, T, Henderson, L, Xu, P, Rambo, B, Xiao, S.Y, Zhao, L, Hart, J, Catenacci, D

Get full text

6609 POSTER RON (MST1R) is a Novel Therapeutic Target for Gastroesophageal Adenocarcinoma by Catenacci, D, Henderson, L, Tretiakova, M, Karrison, T, Salgia, R

Get full text

A Multiscalar Consideration of the Athabascan Migration by Doering, Briana N., Esdale, Julie A., Reuther, Joshua D., Catenacci, Senna D.

“…Genetic and linguistic evidence suggests that, after living in the Subarctic for thousands of years, Northern Athabascans began migrating to the American…”
Get full text

P-138 Margetuximab combined with anti-PD-1 (retifanlimab) or anti-PD-1/LAG-3 (tebotelimab) +/- chemotherapy in first-line therapy of advanced/metastatic HER2+ gastroesophageal junction or gastric cancer by Catenacci, D., Koshiji Rosales, M., Chung, H., Yoon, H., Moehler, M., Kang, Y., Shen, L.

Get full text